De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases

Kebede H. Begna; Jaya Kittur; Jennifer Yui; Naseema Gangat; Mrinal M. Patnaik; Aref Al-Kali; Michelle A. Elliott; William J. Hogan; Mark R. Litzow; Christopher C. Hook; Alexandra P. Wolanskyj; Matthew T. Howard; Curtis A. Hanson; Rhett P. Ketterling; Animesh D. Pardanani; Ayalew Tefferi

doi:10.1111/bjh.17742

De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases

Kebede H. Begna, Jaya Kittur, Jennifer Yui, Naseema Gangat, Mrinal M. Patnaik, Aref Al-Kali, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, Christopher C. Hook, Alexandra P. Wolanskyj, Matthew T. Howard, Curtis A. Hanson, Rhett P. Ketterling, Animesh D. Pardanani, Ayalew Tefferi

Research output: Contribution to journal › Article › peer-review

Abstract

Institutional database search (1999–2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment-induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.

Original language	English (US)
Pages (from-to)	413-416
Number of pages	4
Journal	British journal of haematology
Volume	195
Issue number	3
DOIs	https://doi.org/10.1111/bjh.17742
State	Published - Nov 2021
Externally published	Yes

Keywords

chemotherapy
extramedullary
leukaemia
prognosis
survival

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.17742

Cite this

Begna, K. H., Kittur, J., Yui, J., Gangat, N., Patnaik, M. M., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Wolanskyj, A. P., Howard, M. T., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2021). De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British journal of haematology, 195(3), 413-416. https://doi.org/10.1111/bjh.17742

Begna, KH, Kittur, J, Yui, J, Gangat, N, Patnaik, MM, Al-Kali, A, Elliott, MA, Hogan, WJ, Litzow, MR, Hook, CC, Wolanskyj, AP, Howard, MT, Hanson, CA, Ketterling, RP, Pardanani, AD & Tefferi, A 2021, 'De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases', British journal of haematology, vol. 195, no. 3, pp. 413-416. https://doi.org/10.1111/bjh.17742

@article{a93aeb70611441f895ea65cdd06f562d,

title = "De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases",

abstract = "Institutional database search (1999–2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment-induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.",

keywords = "chemotherapy, extramedullary, leukaemia, prognosis, survival",

author = "Begna, {Kebede H.} and Jaya Kittur and Jennifer Yui and Naseema Gangat and Patnaik, {Mrinal M.} and Aref Al-Kali and Elliott, {Michelle A.} and Hogan, {William J.} and Litzow, {Mark R.} and Hook, {Christopher C.} and Wolanskyj, {Alexandra P.} and Howard, {Matthew T.} and Hanson, {Curtis A.} and Ketterling, {Rhett P.} and Pardanani, {Animesh D.} and Ayalew Tefferi",

note = "Publisher Copyright: {\textcopyright} 2021 British Society for Haematology and John Wiley & Sons Ltd",

year = "2021",

month = nov,

doi = "10.1111/bjh.17742",

language = "English (US)",

volume = "195",

pages = "413--416",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - De novo isolated myeloid sarcoma

T2 - comparative analysis of survival in 19 consecutive cases

AU - Begna, Kebede H.

AU - Kittur, Jaya

AU - Yui, Jennifer

AU - Gangat, Naseema

AU - Patnaik, Mrinal M.

AU - Al-Kali, Aref

AU - Elliott, Michelle A.

AU - Hogan, William J.

AU - Litzow, Mark R.

AU - Hook, Christopher C.

AU - Wolanskyj, Alexandra P.

AU - Howard, Matthew T.

AU - Hanson, Curtis A.

AU - Ketterling, Rhett P.

AU - Pardanani, Animesh D.

AU - Tefferi, Ayalew

PY - 2021/11

Y1 - 2021/11

N2 - Institutional database search (1999–2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment-induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.

AB - Institutional database search (1999–2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment-induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.

KW - chemotherapy

KW - extramedullary

KW - leukaemia

KW - prognosis

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85111837074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111837074&partnerID=8YFLogxK

U2 - 10.1111/bjh.17742

DO - 10.1111/bjh.17742

M3 - Article

C2 - 34346084

AN - SCOPUS:85111837074

SN - 0007-1048

VL - 195

SP - 413

EP - 416

JO - British journal of haematology

JF - British journal of haematology

IS - 3

ER -

De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this